Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 13/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.30 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.30 |
| ▸ | ITGAL | P20701 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797574 | 0.91 | TRPV4 (0.31) | TRPV4TMEM97MDM2TP53ITGB2 | |
| SCHEMBL4913351 | 0.89 | ITGAL (0.33) | ITGB2ICAM1ITGAL | |
| SCHEMBL4638944 | 0.89 | ITGAL (0.33) | ITGB2ICAM1ITGAL | |
| SCHEMBL4799603 | 0.86 | TRPV4 (0.34) | TRPV4 | |
| SCHEMBL4637372 | 0.82 | — | — | |
| SCHEMBL4638957 | 0.82 | — | — | |
| SCHEMBL4864731 | 0.81 | ITGAL (0.40) | ITGB2ICAM1ITGAL | |
| SCHEMBL14209158 | 0.81 | ITGAL (0.40) | ITGB2ICAM1ITGAL | |
| SCHEMBL4866024 | 0.81 | ITGAL (0.40) | ITGB2ICAM1ITGAL | |
| SCHEMBL4912803 | 0.79 | ITGAL (0.37) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375237-B2 | Pyrrolizine compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060052434-A1 | Pyrrolizine compounds useful as anti-inflammatory agents | CEREP S.A. (FR) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052434-A1 | Pyrrolizine compounds useful as anti-inflammatory agents | NFKBIA, TNF, NFKB1 | TRPV4 1660/4885TMEM97 4876/4885MDM2 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.